Ovarian function following immunocontraceptive vaccination of mares using native porcine and recombinant zona pellucida vaccines formulated with a non-Freund's adjuvant and anti-GnRH vaccines
An important determinant in the selection of any contraceptive agent is the impact on ovarian function, both in the short and longer term. In this study, ovarian activity was monitored in mares immunised with one of the following vaccine formulations; native porcine zona pellucida (pZP), recombinant...
Gespeichert in:
Veröffentlicht in: | Theriogenology 2018-10, Vol.120, p.111-116 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 116 |
---|---|
container_issue | |
container_start_page | 111 |
container_title | Theriogenology |
container_volume | 120 |
creator | Nolan, Margaret B. Bertschinger, Henk J. Roth, Robyn Crampton, Michael Martins, Isabela S. Fosgate, Geoffrey T. Stout, Tom A. Schulman, Martin L. |
description | An important determinant in the selection of any contraceptive agent is the impact on ovarian function, both in the short and longer term. In this study, ovarian activity was monitored in mares immunised with one of the following vaccine formulations; native porcine zona pellucida (pZP), recombinant zona pellucida proteins ZP3 and ZP4 (reZP), pZP and reZP combined or a commercially available anti-GnRH vaccine. The ZP antigens were prepared in an adjuvant formulation consisting of 6% polymeric adjuvant (Montanide™ PetGel A, Seppic, France) and 500 μg polyinosinic-polycytidylic acid - TLR3-agonist (Poly(I:C) HMW VacciGrade™, Invivogen, USA). A vehicle-only control group was administered the adjuvant formulation without antigen. Ovarian activity was monitored using clinical observations (transrectal palpation and ultrasonography of the reproductive tract) in addition to blood sampling for serum progesterone and anti-Müllerian hormone (AMH) concentrations while employing a low sampling frequency. Treatments and measurements were initiated in December (southern hemisphere summer) and subsequent data collection was performed in January, February, March and May. Both reZP and anti-GnRH vaccination were associated with clinically evident ovarian suppression in the short term. Ovarian activity in mares administered a reZP or anti-GnRH vaccine was significantly different to adjuvant control and pZP treated mares. Serum AMH concentrations were different between pZP and anti-GnRH treated mares 3.5 months after the final vaccination. Serum AMH concentrations were significantly correlated with mare age, serum progesterone and ovarian volume.
•Immunocontraception of mares using reZP proteins formulated with non-Freund's adjuvant causes ovarian suppression.•Serum AMH concentrations using infrequent sampling techniques are correlated with ovarian volume, progesterone and mare age.•Serum AMH is higher in older than younger, albeit sexually mature, mares. |
doi_str_mv | 10.1016/j.theriogenology.2018.07.044 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2087993758</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0093691X18305922</els_id><sourcerecordid>2087993758</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-12e074251fcb8b7bed8535c0ef577c0ef0558c271ad3df2c755865441d4ef9da3</originalsourceid><addsrcrecordid>eNqNkc1u1DAUhS0EokPhFZAXSLBJsBMnTiQ2qGJapEqVEEjsLMe-mXqU2IN_UrUv11fDYYZK7Fhd_3znXN17EHpHSUkJbT_uy3gL3rgdWDe53X1ZEdqVhJeEsWdoQzveF3VV0-doQ0hfF21Pf56hVyHsCSF129KX6KzOPz1lbIMebxbpjbR4TFZF4_LBTZO7M3aHzTwn65Sz0UsFh2gWwItUylj5h3QjnqWHgFNY8fU1EwfnMwFYWo09KDcPmbcRPzgr8QGmKSmj5ckoi0fn5zTJCBrfmXiLJbbOFlsPyer3AUu9T8uqX_1yNcWl_Xb1JH-NXoxyCvDmVM_Rj-2X7xdXxfXN5deLz9eFYozEglZAOKsaOqqhG_gAumvqRhEYG87XQpqmUxWnUtd6rBTP17ZhjGoGY69lfY4-HH0P3v1KEKKYTVB5GmnBpSAqkvfe17zpMvrpiCrvQvAwioM3eVH3ghKxRij24t8IxRqhIFzkCLP87alTGmbQT-K_mWVgewQgz7sY8CIoA1aBNnnfUWhn_q_Tb3FWvLI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2087993758</pqid></control><display><type>article</type><title>Ovarian function following immunocontraceptive vaccination of mares using native porcine and recombinant zona pellucida vaccines formulated with a non-Freund's adjuvant and anti-GnRH vaccines</title><source>Elsevier ScienceDirect Journals</source><creator>Nolan, Margaret B. ; Bertschinger, Henk J. ; Roth, Robyn ; Crampton, Michael ; Martins, Isabela S. ; Fosgate, Geoffrey T. ; Stout, Tom A. ; Schulman, Martin L.</creator><creatorcontrib>Nolan, Margaret B. ; Bertschinger, Henk J. ; Roth, Robyn ; Crampton, Michael ; Martins, Isabela S. ; Fosgate, Geoffrey T. ; Stout, Tom A. ; Schulman, Martin L.</creatorcontrib><description>An important determinant in the selection of any contraceptive agent is the impact on ovarian function, both in the short and longer term. In this study, ovarian activity was monitored in mares immunised with one of the following vaccine formulations; native porcine zona pellucida (pZP), recombinant zona pellucida proteins ZP3 and ZP4 (reZP), pZP and reZP combined or a commercially available anti-GnRH vaccine. The ZP antigens were prepared in an adjuvant formulation consisting of 6% polymeric adjuvant (Montanide™ PetGel A, Seppic, France) and 500 μg polyinosinic-polycytidylic acid - TLR3-agonist (Poly(I:C) HMW VacciGrade™, Invivogen, USA). A vehicle-only control group was administered the adjuvant formulation without antigen. Ovarian activity was monitored using clinical observations (transrectal palpation and ultrasonography of the reproductive tract) in addition to blood sampling for serum progesterone and anti-Müllerian hormone (AMH) concentrations while employing a low sampling frequency. Treatments and measurements were initiated in December (southern hemisphere summer) and subsequent data collection was performed in January, February, March and May. Both reZP and anti-GnRH vaccination were associated with clinically evident ovarian suppression in the short term. Ovarian activity in mares administered a reZP or anti-GnRH vaccine was significantly different to adjuvant control and pZP treated mares. Serum AMH concentrations were different between pZP and anti-GnRH treated mares 3.5 months after the final vaccination. Serum AMH concentrations were significantly correlated with mare age, serum progesterone and ovarian volume.
•Immunocontraception of mares using reZP proteins formulated with non-Freund's adjuvant causes ovarian suppression.•Serum AMH concentrations using infrequent sampling techniques are correlated with ovarian volume, progesterone and mare age.•Serum AMH is higher in older than younger, albeit sexually mature, mares.</description><identifier>ISSN: 0093-691X</identifier><identifier>EISSN: 1879-3231</identifier><identifier>DOI: 10.1016/j.theriogenology.2018.07.044</identifier><identifier>PMID: 30099144</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Anestrus ; anti-Müllerian hormone ; Horse ; Immunocontraception ; Ovary</subject><ispartof>Theriogenology, 2018-10, Vol.120, p.111-116</ispartof><rights>2018 Elsevier Inc.</rights><rights>Copyright © 2018. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-12e074251fcb8b7bed8535c0ef577c0ef0558c271ad3df2c755865441d4ef9da3</citedby><cites>FETCH-LOGICAL-c440t-12e074251fcb8b7bed8535c0ef577c0ef0558c271ad3df2c755865441d4ef9da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.theriogenology.2018.07.044$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30099144$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nolan, Margaret B.</creatorcontrib><creatorcontrib>Bertschinger, Henk J.</creatorcontrib><creatorcontrib>Roth, Robyn</creatorcontrib><creatorcontrib>Crampton, Michael</creatorcontrib><creatorcontrib>Martins, Isabela S.</creatorcontrib><creatorcontrib>Fosgate, Geoffrey T.</creatorcontrib><creatorcontrib>Stout, Tom A.</creatorcontrib><creatorcontrib>Schulman, Martin L.</creatorcontrib><title>Ovarian function following immunocontraceptive vaccination of mares using native porcine and recombinant zona pellucida vaccines formulated with a non-Freund's adjuvant and anti-GnRH vaccines</title><title>Theriogenology</title><addtitle>Theriogenology</addtitle><description>An important determinant in the selection of any contraceptive agent is the impact on ovarian function, both in the short and longer term. In this study, ovarian activity was monitored in mares immunised with one of the following vaccine formulations; native porcine zona pellucida (pZP), recombinant zona pellucida proteins ZP3 and ZP4 (reZP), pZP and reZP combined or a commercially available anti-GnRH vaccine. The ZP antigens were prepared in an adjuvant formulation consisting of 6% polymeric adjuvant (Montanide™ PetGel A, Seppic, France) and 500 μg polyinosinic-polycytidylic acid - TLR3-agonist (Poly(I:C) HMW VacciGrade™, Invivogen, USA). A vehicle-only control group was administered the adjuvant formulation without antigen. Ovarian activity was monitored using clinical observations (transrectal palpation and ultrasonography of the reproductive tract) in addition to blood sampling for serum progesterone and anti-Müllerian hormone (AMH) concentrations while employing a low sampling frequency. Treatments and measurements were initiated in December (southern hemisphere summer) and subsequent data collection was performed in January, February, March and May. Both reZP and anti-GnRH vaccination were associated with clinically evident ovarian suppression in the short term. Ovarian activity in mares administered a reZP or anti-GnRH vaccine was significantly different to adjuvant control and pZP treated mares. Serum AMH concentrations were different between pZP and anti-GnRH treated mares 3.5 months after the final vaccination. Serum AMH concentrations were significantly correlated with mare age, serum progesterone and ovarian volume.
•Immunocontraception of mares using reZP proteins formulated with non-Freund's adjuvant causes ovarian suppression.•Serum AMH concentrations using infrequent sampling techniques are correlated with ovarian volume, progesterone and mare age.•Serum AMH is higher in older than younger, albeit sexually mature, mares.</description><subject>Anestrus</subject><subject>anti-Müllerian hormone</subject><subject>Horse</subject><subject>Immunocontraception</subject><subject>Ovary</subject><issn>0093-691X</issn><issn>1879-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqNkc1u1DAUhS0EokPhFZAXSLBJsBMnTiQ2qGJapEqVEEjsLMe-mXqU2IN_UrUv11fDYYZK7Fhd_3znXN17EHpHSUkJbT_uy3gL3rgdWDe53X1ZEdqVhJeEsWdoQzveF3VV0-doQ0hfF21Pf56hVyHsCSF129KX6KzOPz1lbIMebxbpjbR4TFZF4_LBTZO7M3aHzTwn65Sz0UsFh2gWwItUylj5h3QjnqWHgFNY8fU1EwfnMwFYWo09KDcPmbcRPzgr8QGmKSmj5ckoi0fn5zTJCBrfmXiLJbbOFlsPyer3AUu9T8uqX_1yNcWl_Xb1JH-NXoxyCvDmVM_Rj-2X7xdXxfXN5deLz9eFYozEglZAOKsaOqqhG_gAumvqRhEYG87XQpqmUxWnUtd6rBTP17ZhjGoGY69lfY4-HH0P3v1KEKKYTVB5GmnBpSAqkvfe17zpMvrpiCrvQvAwioM3eVH3ghKxRij24t8IxRqhIFzkCLP87alTGmbQT-K_mWVgewQgz7sY8CIoA1aBNnnfUWhn_q_Tb3FWvLI</recordid><startdate>20181015</startdate><enddate>20181015</enddate><creator>Nolan, Margaret B.</creator><creator>Bertschinger, Henk J.</creator><creator>Roth, Robyn</creator><creator>Crampton, Michael</creator><creator>Martins, Isabela S.</creator><creator>Fosgate, Geoffrey T.</creator><creator>Stout, Tom A.</creator><creator>Schulman, Martin L.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20181015</creationdate><title>Ovarian function following immunocontraceptive vaccination of mares using native porcine and recombinant zona pellucida vaccines formulated with a non-Freund's adjuvant and anti-GnRH vaccines</title><author>Nolan, Margaret B. ; Bertschinger, Henk J. ; Roth, Robyn ; Crampton, Michael ; Martins, Isabela S. ; Fosgate, Geoffrey T. ; Stout, Tom A. ; Schulman, Martin L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-12e074251fcb8b7bed8535c0ef577c0ef0558c271ad3df2c755865441d4ef9da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Anestrus</topic><topic>anti-Müllerian hormone</topic><topic>Horse</topic><topic>Immunocontraception</topic><topic>Ovary</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nolan, Margaret B.</creatorcontrib><creatorcontrib>Bertschinger, Henk J.</creatorcontrib><creatorcontrib>Roth, Robyn</creatorcontrib><creatorcontrib>Crampton, Michael</creatorcontrib><creatorcontrib>Martins, Isabela S.</creatorcontrib><creatorcontrib>Fosgate, Geoffrey T.</creatorcontrib><creatorcontrib>Stout, Tom A.</creatorcontrib><creatorcontrib>Schulman, Martin L.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Theriogenology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nolan, Margaret B.</au><au>Bertschinger, Henk J.</au><au>Roth, Robyn</au><au>Crampton, Michael</au><au>Martins, Isabela S.</au><au>Fosgate, Geoffrey T.</au><au>Stout, Tom A.</au><au>Schulman, Martin L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ovarian function following immunocontraceptive vaccination of mares using native porcine and recombinant zona pellucida vaccines formulated with a non-Freund's adjuvant and anti-GnRH vaccines</atitle><jtitle>Theriogenology</jtitle><addtitle>Theriogenology</addtitle><date>2018-10-15</date><risdate>2018</risdate><volume>120</volume><spage>111</spage><epage>116</epage><pages>111-116</pages><issn>0093-691X</issn><eissn>1879-3231</eissn><abstract>An important determinant in the selection of any contraceptive agent is the impact on ovarian function, both in the short and longer term. In this study, ovarian activity was monitored in mares immunised with one of the following vaccine formulations; native porcine zona pellucida (pZP), recombinant zona pellucida proteins ZP3 and ZP4 (reZP), pZP and reZP combined or a commercially available anti-GnRH vaccine. The ZP antigens were prepared in an adjuvant formulation consisting of 6% polymeric adjuvant (Montanide™ PetGel A, Seppic, France) and 500 μg polyinosinic-polycytidylic acid - TLR3-agonist (Poly(I:C) HMW VacciGrade™, Invivogen, USA). A vehicle-only control group was administered the adjuvant formulation without antigen. Ovarian activity was monitored using clinical observations (transrectal palpation and ultrasonography of the reproductive tract) in addition to blood sampling for serum progesterone and anti-Müllerian hormone (AMH) concentrations while employing a low sampling frequency. Treatments and measurements were initiated in December (southern hemisphere summer) and subsequent data collection was performed in January, February, March and May. Both reZP and anti-GnRH vaccination were associated with clinically evident ovarian suppression in the short term. Ovarian activity in mares administered a reZP or anti-GnRH vaccine was significantly different to adjuvant control and pZP treated mares. Serum AMH concentrations were different between pZP and anti-GnRH treated mares 3.5 months after the final vaccination. Serum AMH concentrations were significantly correlated with mare age, serum progesterone and ovarian volume.
•Immunocontraception of mares using reZP proteins formulated with non-Freund's adjuvant causes ovarian suppression.•Serum AMH concentrations using infrequent sampling techniques are correlated with ovarian volume, progesterone and mare age.•Serum AMH is higher in older than younger, albeit sexually mature, mares.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30099144</pmid><doi>10.1016/j.theriogenology.2018.07.044</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0093-691X |
ispartof | Theriogenology, 2018-10, Vol.120, p.111-116 |
issn | 0093-691X 1879-3231 |
language | eng |
recordid | cdi_proquest_miscellaneous_2087993758 |
source | Elsevier ScienceDirect Journals |
subjects | Anestrus anti-Müllerian hormone Horse Immunocontraception Ovary |
title | Ovarian function following immunocontraceptive vaccination of mares using native porcine and recombinant zona pellucida vaccines formulated with a non-Freund's adjuvant and anti-GnRH vaccines |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T23%3A00%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ovarian%20function%20following%20immunocontraceptive%20vaccination%20of%20mares%20using%20native%20porcine%20and%20recombinant%20zona%20pellucida%20vaccines%20formulated%20with%20a%20non-Freund's%20adjuvant%20and%20anti-GnRH%20vaccines&rft.jtitle=Theriogenology&rft.au=Nolan,%20Margaret%20B.&rft.date=2018-10-15&rft.volume=120&rft.spage=111&rft.epage=116&rft.pages=111-116&rft.issn=0093-691X&rft.eissn=1879-3231&rft_id=info:doi/10.1016/j.theriogenology.2018.07.044&rft_dat=%3Cproquest_cross%3E2087993758%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2087993758&rft_id=info:pmid/30099144&rft_els_id=S0093691X18305922&rfr_iscdi=true |